The Hypocretin Receptor pipeline drugs market research report outlays comprehensive information on the Hypocretin Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Hypocretin Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Respiratory, Metabolic Disorders, and Toxicology which include the indications Narcolepsy, Insomnia, Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease (COPD), Obesity, and Opioid Induced Side Effects. It also reviews key players involved in Hypocretin Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Hypocretin Receptor pipeline targets constitutes close to 27 molecules. Out of which, approximately 26 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 6, 4, 6, 7, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Hypocretin Receptor overview
The hypocretin receptor, also known as the orexin receptor, is a G-protein-coupled receptor that binds to the neuropeptide orexin. There are two variants of the receptor, OX1 and OX2, each encoded by a different gene. The orexin system consists of two neuropeptides, orexin-A/hypocretin-1 and orexin-B/hypocretin-2. The orexins bind to and activate two G-protein–coupled receptors (GPCRs), orexin receptor type 1 (OX1R) and type 2 (OX2R). The hypocretin type 1 receptor binds only to hypocretin-1, while the hypocretin type 2 receptor can bind to both type 1 and type 2 ligands.
For a complete picture of Hypocretin Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
